The role of autologous hematopoietic progenitor and cell reinfusion for intensive chemotherapy in women with poor-prognosis breast cancer. Clinical studies with ex-vivo expanded cells produced with the Aastrom Replicell (R) technology

Authors
Chabannon, C Novakovitch, G Blache, JL Olivero, S Camerlo, J Genre, D Maraninchi, D Viens, P
Citation
C. Chabannon et al., The role of autologous hematopoietic progenitor and cell reinfusion for intensive chemotherapy in women with poor-prognosis breast cancer. Clinical studies with ex-vivo expanded cells produced with the Aastrom Replicell (R) technology, HEM CELL TH, 41(2), 1999, pp. 78-81
Citations number
19
Categorie Soggetti
Hematology,"Cardiovascular & Hematology Research
Journal title
HEMATOLOGY AND CELL THERAPY
ISSN journal
12693286 → ACNP
Volume
41
Issue
2
Year of publication
1999
Pages
78 - 81
Database
ISI
SICI code
1269-3286(199904)41:2<78:TROAHP>2.0.ZU;2-G
Abstract
In recent years, we have initiated two clinical studies, to evaluate the us efulness of ex-vivo expanded cells in patients with breast cancer who recei ve sequential high-dose chemotherapy. Ex-vivo expanded cells were produced from autologous cryopreserved bone marrow nucleated cells, using a biomedic al device. The Aastrom Replicell(R) system cultures cells in animal serum-r eplete medium, with a combination of flt3-L, PIXY321 and Epo, for 12 days. The initial pilot trial was set up to establish the feasibility and safety of the technique: 6 patients completed the study. An ongoing randomized stu dy searches to establish whether ex-vivo expanded cells provide a clinical benefit.